- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11. | FDA unveils swift route to market for personalised drugs | ||
| 13.11. | Change at the top of Recursion as co-founder leaves CEO role | ||
| 12.11. | One Drop founder announces broad market CGM on Frontiers stage | ||
| 12.11. | Alkermes breaks new ground in narcolepsy with orexin drug | ||
| 12.11. | Bayer beats expectations with tougher times looming | ||
| 12.11. | AI features in UK plan to reduce animal testing | ||
| 12.11. | NHS braces for thousands of redundancies | ||
| 12.11. | FDA appoints veteran Pazdur to replace Tidmarsh | ||
| 11.11. | Trial sets up filing for enGene bladder cancer gene therapy | ||
| 11.11. | Daiichi Sankyo launches its STING operation against cancer | ||
| 11.11. | Ireland's Mallinckrodt closes spinout, rebrands as Keenova | ||
| 11.11. | Queer Eye's Tan France to front Lilly obesity campaign | ||
| 11.11. | AHA: MSD's oral PCSK9 matches injectables | ||
| 10.11. | Roche's oral MS hope fenebrutinib hits the mark in phase 3 | ||
| 10.11. | AHA: AZ's baxdrostat impresses in resistant hypertension | ||
| 10.11. | AHA: Cash for drug adherence study has disappointing result | ||
| 07.11. | Intellia shares fall after hospitalised CRISPR patient dies | ||
| 07.11. | Braveheart, AAVantgarde rounds head recent biofinancings | ||
| 07.11. | Eisai settles Lenvima patent dispute with Torrent Pharma | ||
| 07.11. | GLP-1s feature in second batch of national priority vouchers | ||
| 06.11. | Novo, Lilly sign MFN pricing deal with Trump administration | ||
| 06.11. | J&J adds first new indication for Caplyta since takeover | ||
| 06.11. | Lilly reports 20% weight loss with amylin-targeting drug | ||
| 06.11. | AZ's Q3 sales reach record $15bn, but it holds guidance | ||
| 06.11. | Novo Nordisk fights back with oral GLP-1 data in obesity |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .